That's correct. Remember in my original research narrative and in many subsequent posts how I mentioned caspase 3 and how the major beneficial action of minocycline on MS was by inhibiting caspase 3 activation, and not really acting directly as an anti-bacterial, per se? If you interfere with caspase 3 activation and its subsequent complex effects on mitochondria, thereby increasing mitochondria's resistence to damaging effects, etc., and inhibiting apoptosis (i.e. neuroprotection); you therefore can help MS.
Therefore, if they can create a drug now that has as its main action be manipulation of caspase 3 processes in some way or another, then you may have adjunctive drug treatment for MS. Which is what I dare say they apparently are now doing.
Since I've been saying this for months, I won't expound any farther and waste anyone's time. It's pretty complex anyway, but that's the bottom line. Caspase 3.
Interesting article, Arron! Glad you posted it. I rest my case.
EDIT: Oops, I have to correct myself. It wasn't mentioned in my original narrative. I had posted shortly thereafter the caspase 3 connection and my research on it. Sorry.